For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from ...

Researchers have identified a specific form of the tau protein that is responsible for ... MAPT knockout human iPSC-derived neurons to amyloid beta and phosphorylated TAU-induced neuronal ...

which has just completed enrolment in a phase III trial of a tau-targeting drug in mild-to-moderate AD. Despite an R&D spend of around $15bn, a total of 20 beta amyloid protein-targeting drugs ...

An experimental drug has shown promise in preventing Alzheimer’s for people at higher risk of developing the disease.

A stem cell therapy trial aimed at reducing neuroinflammation in patients with presymptomatic Alzheimer’s disease is underway ...

A comprehensive Thought Leaders Invited Review in Brain Medicine highlights the crucial role of CD2-associated protein (CD2AP ...

Figure 5: Age-dependent increase in insoluble tau in P301L (JNPL3) mouse brains. We have reported a transgenic mouse line, JNPL3, expressing human tau with the P301L mutation that develops NFT ...

The researchers have been testing amyloid-removing therapies ... with sticky plaques made from beta amyloid proteins and toxic tangles made of a protein called tau. They theorized that removing ...

A research team at the University of Cologne has made a significant breakthrough in understanding the role of the tau protein in ... iPSC-derived neurons to amyloid beta and phosphorylated TAU ...

An oral small molecule from New York-based biotech Oligomerix curbed the tangling of tau protein in the brains of mice that ...